Review

To repeat or not to repeat? Measuring bone mineral density during anti-resorptive therapy or a drug holiday

Tayyab S. Khan, MD, Partha Sinha, MD, PhD and Harold Rosen, MD
Cleveland Clinic Journal of Medicine March 2023, 90 (3) 173-180; DOI: https://doi.org/10.3949/ccjm.90a.22071

Article Figures & Data

Figures

  • Figure 1
    Figure 1

    Waterfall plots demonstrating the percent changes in bone mineral density on treatment with denosumab vs placebo at the lumbar spine (A) and total hip (B) over 36 months in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months study. While many patients in the placebo group lost bone mineral density, few in the denosumab group did. Almost none of the participants on denosumab lost a significant amount of bone mineral density (> 5%) over 36 months.

    Reprinted from Bolognese MA, Teglbjærg CS, Zanchetta JR, et al. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom 2013; 16(2):147–153. doi:10.1016/j.jocd.2012.02.006 with permission from Elsevier.

  • Figure 2
    Figure 2

    Changes in total hip bone mineral density (BMD) 5 years after completing a 5-year course of treatment with alendronate in the long-term extension of the Fracture Intervention Trial. Many patients had no significant hip bone loss, but a substantial minority had more than 5% bone loss, and an even smaller minority had more than 10% bone loss.

    Reprinted from McNabb BL, Vittinghoff E, Schwartz AV, et al. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J Bone Miner Res 2013; 28(6):1319–1327. doi:10.1002/jbmr.1864 with permission from John Wiley and Sons.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects